1041.7000 -1.30 (-0.12%)
NSE Jul 28, 2026 15:49 PM
Volume: 89,685
 

Axis Direct
Strides reported Q4'17 EBITDA of Rs 1.56bn, 28% below our expectations, hit by challenging environment across key markets. EBITDA including other income was Rs 2.1 bn, which is ~95% of H2'17 EBITDA guidance.
Promoters pledged 10.83% of shares in last quarter. Total pledge stands at 38.10% of promoter holdings
More from Strides Pharma Science Ltd.
Recommended